Russia's First Melanoma Vaccine Patient Recovers Successfully
The first patient in Russia to receive a personalized mRNA vaccine for melanoma is recovering successfully, and 12 additional vaccines have been synthesized for other patients, with plans to treat at least 20 patients by year-end. The vaccines are being developed by the Gamaleya Research Center in collaboration with the Gertsen Oncology Institute.
Consensus
- The first patient in Russia to receive the personalized mRNA vaccine for melanoma is being treated successfully.
- 12 mRNA vaccines for melanoma have been synthesized for patients.
- The vaccines are being developed by the National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya under the leadership of Alexander Gintsburg.
- The vaccines are intended for use in the Gertsen Oncology Institute in Moscow.
- The goal is to treat at least 20 melanoma patients by the end of the year.
- The final stages of vaccine development are underway, with delivery to the Gertsen Institute planned for September–October.
- The first patient received the vaccine on April 1.
- The vaccines are based on the same platform used for the 'Neoonkovak' melanoma vaccine.
Points of divergence
- On August 3, information emerged about a prototype vaccine for non-small cell lung cancer developed by the Gamaleya Center. — vm
- Three new cancer vaccines are being prepared for application in Russia, including ones for bladder cancer, small cell lung cancer, and colorectal cancer. — m24
- The vaccines are expected to be delivered to the Gertsen Center within the next two months. — riamo
- There are about 20 people in line to receive the vaccine. — m24
Coverage (5 sources)
- It has become known the condition of the first patient vaccinated against skin cancer in Russia — Вести
- Ginzburg spoke about plans to use melanoma vaccines — РИАМО
- Ginzburg: Vaccines against melanoma synthesized for 12 more patients in Russia — Вечерняя Москва
- In Russia, individual vaccines were prepared for 12 patients with skin cancer — Вести
- New melanoma vaccines synthesized for 12 patients — Москва 24
Key entities
- Russia
- Alexander Ginzburg
- RIA Novosti
- Moscow
- Ministry of Health
- RAS
- Gamaleya Research Institute of Epidemiology and Microbiology
- National Research Center for Epidemiology and Microbiology (NRECM) named after N.F. Gamalei
- Herzen
- Yulia Ivanko Vaccina
- Gamaleya Institute
- Moscow Scientific Research Oncological Institute named after Herzen
- National Research Center for Epidemiology and Microbiology named after N.F. Gamalei
- Gercen Scientific Research Oncological Institute
More on Alexander Ginzburg
- Moscow, September 13: A Russian vaccine that protects against…
- Russia identifies drug-resistant TB strain EurA1.1
- Some cancers may be beaten in 3-6 years